HER2-POSITIVE BREAST CANCER
Clinical trials for HER2-POSITIVE BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HER2-POSITIVE BREAST CANCER trials appear
Sign up with your email to follow new studies for HER2-POSITIVE BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo tested for Tough-to-Treat cancers
Disease control TerminatedThis early-stage study tested a new drug called BDC-1001, both by itself and combined with an existing immunotherapy drug (nivolumab), for people with advanced cancers that have a specific marker called HER2. The main goals were to find safe doses and see if the treatments could …
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Bolt Biotherapeutics, Inc. • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
Could some breast cancer patients avoid surgery altogether?
Disease control TerminatedThis study explored whether women with a specific type of early-stage, HER2-positive breast cancer could safely skip surgery and lymph node removal. To qualify, patients first needed to have no detectable cancer left after completing a standard course of targeted drug therapy. Th…
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Fundacio Clinic Barcelona • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
Trial halted early: did this combo help control tough brain tumors?
Disease control TerminatedThis study tested whether adding the drug ASLAN001 to standard chemotherapy (capecitabine) could help control brain tumors in people with a specific type of breast cancer (HER2-positive). It was for patients whose brain tumors had started growing again after radiation treatment. …
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: National Cancer Centre, Singapore • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
Trial for tough breast cancer cases halted early
Disease control TerminatedThis study tested an experimental drug called BDC-1001, both alone and combined with an existing drug (pertuzumab), for people with advanced HER2-positive breast cancer that had worsened after standard treatments. The goal was to see if the treatment could shrink tumors and was s…
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE2 • Sponsor: Bolt Biotherapeutics, Inc. • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
Early halt for brain cancer combo trial
Disease control TerminatedThis early-stage study aimed to see if combining three cancer drugs with a precise type of radiation could better control breast cancer that had spread to the brain. It was designed for people with a specific type of breast cancer (HER2-positive) and up to 10 small brain tumors. …
Matched conditions: HER2-POSITIVE BREAST CANCER
Phase: PHASE1 • Sponsor: Baptist Health South Florida • Aim: Disease control
Last updated Mar 23, 2026 15:16 UTC